About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)

Clinicaltrials.gov identifier NCT03930953

Recruitment Status Recruiting

First Posted April 29, 2019

Last update posted June 11, 2020

Study Description

Brief summary:

CC-99282-NHL-001 study is a Phase I dose escalation and expansion clinical study of CC-99282 administered alone and in combination with rituximab in subjects with relapsed or refractory non-hodgkin Lymphomas (R/R NHL).

  • Condition or Disease:Lymphoma, Non-Hodgkin
  • Intervention/Treatment: Drug: CC-99282
    Drug: rituximab
  • Phase: Phase 1
Detailed Description

Subjects with R/R NHL who have failed at least 2 lines of therapy (or have received at least one prior line of standard therapy and are not eligible for any other therapy). The dose escalation will evaluate the safety and tolerability of escalating doses of CC-99282 in R/R DLBCL and/or R/R FL subjects to determine the MTD of CC-99282 as monotherapy. The dose expansion will further evaluate the safety and preliminary efficacy of single agent CC-99282 administered at or below MTD in subjects with R/R DLBCL and NHL. Part B will also evaluate the safety and preliminary efficacy of CC-99282 in combination with rituximab in subjects with R/R DLBCL and R/R FL.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 100 participants
  • Intervention Model: Sequential Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R iNHL).
  • Actual Study Start Date: May 2019
  • Estimated Primary Completion Date: June 2023
  • Estimated Study Completion Date: May 2024
Arms and interventions
Arm Intervention/treatment
Experimental: Administration of CC-99282
Escalating doses of CC-99282 administered orally once daily on intermittent schedules up to 2 years.
Drug: CC-99282
CC-99282
Experimental: CC-99282 + rituximab
CC-99282 administered orally once daily on intermittent schedule with rituximab intravenously (IV) 375 mg/m2 weekly in Cycle 1, every 28 days in C2-6, then every 8 weeks through 2 years.
Drug: CC-99282
CC-99282

Drug: rituximab
rituximab
Outcome Measures
  • Primary Outcome Measures: 1. Dose Limiting Toxicity (DLT) [ Time Frame: up to 28 days in Cycle 1 ]
    Number of subjects with a DLT
  • 2. Maximum tolerated dose (MTD) [ Time Frame: up to 28 days in cycle 1 ]
    The highest dose of CC-99282 associated with acceptable safety and tolerability
  • 3. Adverse Events (AEs) [ Time Frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 2 years) ]
    Type, frequency, seriousness, severity and relationship of AEs to CC-99282 and rituximab; changes from baseline in clinically-relevant physical findings, vital signs, selected analytes, ECGs, LVEF and ECOG
  • Secondary Outcome Measures: 1. Pharmacokinetics - Cmax [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]
    Maximum observed plasma concentration
  • 2. Pharmacokinetics - AUC [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]
    Area under the plasma concentration-time curve
  • 3. Pharmacokinetics - Tmax [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]
    Time to Cmax
  • 4. Pharmacokinetics - t1/2 [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]
    Terminal-phase elimination half-life
  • 5. Pharmacokinetics - CL/F [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]
    Apparent total clearance of the drug from plasma after oral administration
  • 6. Pharmacokinetics - V/F [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]
    Apparent volume of distribution during terminal phase after non-intravenous administration
  • 7. Objective response rate (ORR) [ Time Frame: up to approximately 3 years ]
    Sum of partial response (PR) plus complete response (CR) determined by the Lugano Classification for NHL and by the modified International PCNSL collaborative Group (IPCG) criteria
  • 8. Time to response (TTR) [ Time Frame: up to approximately 3 years ]
    Time from first dose of CC-99282 to the first documentation of response ≥ PR
  • 9. Duration of response (DoR) [ Time Frame: up to approximately 3 years ]
    Time from first documentation of response (≥ PR) to the first documentation of PD or death
  • 10. Progression free survival [ Time Frame: up to approximately 3 years ]
    Time from first dose of CC-99282 to the first occurrence of disease progression or death from any cause
  • 11. Overall survival [ Time Frame: up to approximately 3 years ]
    Time from first dose of CC-99282 to death from any cause
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. Subject is ≥18 years of age at the time of signing the informed consent form (ICF).

2. Subject has a history of NHL with relapsed or refractory disease

3. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or
2.

4. Subjects must have the following laboratory values:

1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support for 7
days (14 days if pegfilgastrim)

2. Hemoglobin (Hgb) ≥ 8 g/dL

3. Platelets (plt) ≥ 75 x 109/L without transfusion for 7 days

4. Serum bilirubin ≤ 1.5 x ULN (upper limit of normal).

5. AST/SGOT and ALT/SGPT ≤ 2.5X ULN

6. Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault
equation.

5. Agree to follow the CC-99282 Pregnancy Prevention Plan (PPP)

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subject has life expectancy ≤ 2 months.

2. Subject has received prior systemic anti-cancer treatment (approved or
investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is
shorter.

3. Subject has symptomatic CNS involvement of disease (does not apply to PCNSL subjects
in Part B).

4. Persistent diarrhea or malabsorption≥ Grade 2 , despite medical management

5. Subject is on chronic systemic immunosuppressive therapy or corticosteroids (eg,
prednisone or equivalent not to exceed 10 mg per day within the last 14 days) or
subjects with clinically significant graft-versus-host disease (GVHD).

6. Subject had prior autologous SCT ≤ 3 months prior to starting CC 99282. If subject had
prior autologous SCT > 3 months prior to the start of CC-99282, any treatment-related
toxicity is unresolved (grade > 1).

7. Subject had prior allogeneic SCT with either standard or reduced intensity
conditioning ≤ 6 months prior to starting CC-99282. If subject had prior allogenic SCT
> 6 months prior to the start of CC-99282, any treatment-related toxicity is
unresolved (grade > 1).

8. Impaired cardiac function or clinically significant cardiac disease

Contacts and Locations
Contacts

Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
Show 11 Study Locations
Sponsors and Collaborators

Celgene

Investigators

Study Director: Poliana Patah, MD, PhD Bristol-Myers Squibb

More Information
  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT03930953 History of Changes
  • Other Study ID Numbers: CC-99282-NHL-001, U1111-1224-5399, 2018-003235-29
  • First Posted: April 29, 2019 Key Record Dates
  • Last Update Posted: June 11, 2020
  • Last Verified: June 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Yes
  • Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Supporting Materials: Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
  • Time Frame: See Plan Description
  • Access Criteria: See Plan Description
  • URL: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: Non-Hodgkin Lymphomas
    Safety
    Efficacy
    CC-99282
    Rituximab
    Relapsed
    Refractory
  • Additional relevant MeSH terms: Lymphoma Lymphoma, Non-Hodgkin